- Home
- AUST vs EDSA Comparison
AUST vs EDSA Comparison
Compare AUST & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- EDSA
- Stock Information
- Founded
- AUST 2020
- EDSA 2015
- Country
- AUST Canada
- EDSA Canada
- Employees
- AUST N/A
- EDSA N/A
- Industry
- AUST
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- EDSA Health Care
- Exchange
- AUST Nasdaq
- EDSA Nasdaq
- Market Cap
- AUST 21.1M
- EDSA 17.2M
- IPO Year
- AUST 2022
- EDSA N/A
- Fundamental
- Price
- AUST $1.73
- EDSA $2.40
- Analyst Decision
- AUST
- EDSA Strong Buy
- Analyst Count
- AUST 0
- EDSA 2
- Target Price
- AUST N/A
- EDSA $13.00
- AVG Volume (30 Days)
- AUST 129.7K
- EDSA 17.3K
- Earning Date
- AUST 11-05-2025
- EDSA 08-08-2025
- Dividend Yield
- AUST N/A
- EDSA N/A
- EPS Growth
- AUST N/A
- EDSA N/A
- EPS
- AUST N/A
- EDSA N/A
- Revenue
- AUST N/A
- EDSA N/A
- Revenue This Year
- AUST N/A
- EDSA N/A
- Revenue Next Year
- AUST N/A
- EDSA N/A
- P/E Ratio
- AUST N/A
- EDSA N/A
- Revenue Growth
- AUST N/A
- EDSA N/A
- 52 Week Low
- AUST $0.87
- EDSA $1.55
- 52 Week High
- AUST $3.19
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- AUST 61.44
- EDSA 53.67
- Support Level
- AUST $1.78
- EDSA $2.41
- Resistance Level
- AUST $1.95
- EDSA $2.48
- Average True Range (ATR)
- AUST 0.13
- EDSA 0.10
- MACD
- AUST 0.01
- EDSA -0.01
- Stochastic Oscillator
- AUST 65.18
- EDSA 48.28
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.